Bristol's Lagging OTC Growth Leads To Accelerated Divestiture Talks
This article was originally published in The Pink Sheet Daily
A lack of foreseeable growth may precipitate the imminent sale of Bristol-Myers Squibb's line of OTCs
You may also be interested in...
With landmark advisory committee meetings coming up, we take a look back at some of the memorable panel meetings over the last 20 years. This is Part II in the series.
With two landmark advisory committee meetings coming up, the Pink Sheet reflects on some of the most memorable panel meetings over the last 20 years.
NASEM is expected to issue a highly anticipated report in early 2021 on solutions to address Rx vial drug wastage.